1.07
price up icon3.88%   0.04
after-market アフターアワーズ: 1.05 -0.02 -1.87%
loading
前日終値:
$1.03
開ける:
$1.06
24時間の取引高:
268.24K
Relative Volume:
0.37
時価総額:
$79.23M
収益:
$8.23M
当期純損益:
$-32.49M
株価収益率:
-1.8136
EPS:
-0.59
ネットキャッシュフロー:
$-19.91M
1週間 パフォーマンス:
+1.90%
1か月 パフォーマンス:
-26.21%
6か月 パフォーマンス:
-18.32%
1年 パフォーマンス:
+12.03%
1日の値動き範囲:
Value
$1.05
$1.09
1週間の範囲:
Value
$0.99
$1.09
52週間の値動き範囲:
Value
$0.7564
$2.12

Clearside Biomedical Inc Stock (CLSD) Company Profile

Name
名前
Clearside Biomedical Inc
Name
セクター
Healthcare (1181)
Name
電話
678-270-3631
Name
住所
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Name
職員
30
Name
Twitter
@clearsidebio
Name
次回の収益日
2024-11-12
Name
最新のSEC提出書
Name
CLSD's Discussions on Twitter

Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2021-12-15 再開されました Wedbush Outperform
2021-07-29 開始されました H.C. Wainwright Buy
2020-05-13 開始されました ROTH Capital Buy
2019-08-09 ダウングレード Needham Buy → Hold
2018-11-05 ダウングレード Cowen Outperform → Market Perform
2018-11-05 ダウングレード JP Morgan Overweight → Underweight
2018-11-05 ダウングレード Stifel Buy → Hold
2018-03-06 繰り返されました Needham Buy
2017-05-25 開始されました JMP Securities Mkt Outperform
2017-02-24 開始されました JP Morgan Overweight
2016-11-10 繰り返されました Needham Buy
2016-10-24 繰り返されました Stifel Buy
すべてを表示

Clearside Biomedical Inc (CLSD) 最新ニュース

pulisher
03:35 AM

Clearside Biomedical (CLSD) to Release Earnings on Tuesday - MarketBeat

03:35 AM
pulisher
Nov 04, 2024

Clearside Biomedical, Inc. (NASDAQ:CLSD) Insider Purchases $36,500.00 in Stock - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Clearside Biomedical chief medical officer buys $36,500 in stock - Investing.com

Nov 04, 2024
pulisher
Nov 04, 2024

Clearside Biomedical chief medical officer buys $36,500 in stock By Investing.com - Investing.com UK

Nov 04, 2024
pulisher
Nov 04, 2024

Clearside Biomedical names new board chair By Investing.com - Investing.com Australia

Nov 04, 2024
pulisher
Nov 04, 2024

Clearside Biomedical names new board chair - Investing.com

Nov 04, 2024
pulisher
Nov 04, 2024

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors - GlobeNewswire

Nov 04, 2024
pulisher
Oct 31, 2024

Clearside Biomedical to Report Third Quarter 2024 Financial - GlobeNewswire

Oct 31, 2024
pulisher
Oct 31, 2024

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024 - StockTitan

Oct 31, 2024
pulisher
Oct 28, 2024

Clearside’s CLS-AX shows promise in treatment of wet age-related macular degeneration - 2 Minute Medicine

Oct 28, 2024
pulisher
Oct 28, 2024

Brokerages Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Price Target at $5.17 - MarketBeat

Oct 28, 2024
pulisher
Oct 25, 2024

Short Interest in Clearside Biomedical, Inc. (NASDAQ:CLSD) Rises By 646.6% - MarketBeat

Oct 25, 2024
pulisher
Oct 23, 2024

Clearside Biomedical advances CLS-AX into Phase 3 trials By Investing.com - Investing.com Nigeria

Oct 23, 2024
pulisher
Oct 22, 2024

Clearside Biomedical Inc Still Hasn’t Convinced Analysts? - Stocks Register

Oct 22, 2024
pulisher
Oct 22, 2024

Clearside Biomedical advances CLS-AX into Phase 3 trials - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting - ForexTV.com

Oct 22, 2024
pulisher
Oct 22, 2024

Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and - GlobeNewswire

Oct 22, 2024
pulisher
Oct 20, 2024

Clearside Biomedical (NASDAQ:CLSD) Stock Rating Upgraded by StockNews.com - Defense World

Oct 20, 2024
pulisher
Oct 18, 2024

Clearside Biomedical (NASDAQ:CLSD) Rating Increased to Hold at StockNews.com - MarketBeat

Oct 18, 2024
pulisher
Oct 16, 2024

Healthy Upside Potential: Clearside Biomedical Inc (CLSD) - SETE News

Oct 16, 2024
pulisher
Oct 15, 2024

Investing in Clearside Biomedical Inc (CLSD): What You Must Know - Knox Daily

Oct 15, 2024
pulisher
Oct 14, 2024

Clearside Biomedical (NASDAQ:CLSD) Stock Rating Reaffirmed by Chardan Capital - MarketBeat

Oct 14, 2024
pulisher
Oct 14, 2024

Ratio Analysis: Unpacking Clearside Biomedical Inc (CLSD)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

Results from Clearside Biomedical Inc (CLSD) show risk - US Post News

Oct 14, 2024
pulisher
Oct 14, 2024

CLSD’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Oct 14, 2024
pulisher
Oct 11, 2024

Clearside Biomedical Inc [NASDAQ: CLSD] Sees Increase in Stock Value - Knox Daily

Oct 11, 2024
pulisher
Oct 10, 2024

How does Clearside Biomedical Inc (CLSD) change from a tortoise to a hare? - SETE News

Oct 10, 2024
pulisher
Oct 10, 2024

Needham & Company LLC Raises Clearside Biomedical (NASDAQ:CLSD) Price Target to $6.00 - MarketBeat

Oct 10, 2024
pulisher
Oct 10, 2024

Clearside stock falls 12% amid Phase 2 data for CLS-AX - MSN

Oct 10, 2024
pulisher
Oct 10, 2024

Clearside Biomedical's Stock (CLSD) Dips On Trial Despite Reiterated Confidence From Analyst - AskTraders

Oct 10, 2024
pulisher
Oct 10, 2024

Clearside’s wet AMD drug-device combo shines in Phase IIb study - Clinical Trials Arena

Oct 10, 2024
pulisher
Oct 10, 2024

Financial Metrics Unveiled: Clearside Biomedical Inc (CLSD)’s Key Ratios in the Spotlight - The Dwinnex

Oct 10, 2024
pulisher
Oct 09, 2024

Clearside Clears Way For Phase III After Positive CLS-AX Results In Wet AMD - Scrip

Oct 09, 2024
pulisher
Oct 09, 2024

Clearside stock falls 12% amid Phase 2 data for CLS-AX (NASDAQ:CLSD) - Seeking Alpha

Oct 09, 2024
pulisher
Oct 09, 2024

Traders Buy Large Volume of Call Options on Clearside Biomedical (NASDAQ:CLSD) - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Clearside Biomedical (NASDAQ:CLSD) Files 8-K with the SEC Regarding Latest Developments - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

Clearside Biomedical’s Promising Phase 2b ODYSSEY Trial Outcomes - TipRanks

Oct 09, 2024
pulisher
Oct 09, 2024

A stock that deserves closer examination: Clearside Biomedical Inc (CLSD) - US Post News

Oct 09, 2024
pulisher
Oct 09, 2024

Top Premarket Gainers - Marketscreener.com

Oct 09, 2024
pulisher
Oct 09, 2024

Clearside reports success in wet AMD trial - Investing.com

Oct 09, 2024
pulisher
Oct 09, 2024

Clearside Biomedical Announces Positive Topline Results - GlobeNewswire

Oct 09, 2024
pulisher
Oct 09, 2024

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes - Yahoo Finance

Oct 09, 2024
pulisher
Oct 08, 2024

CLSD’s latest rating updates from top analysts. - Knox Daily

Oct 08, 2024
pulisher
Oct 08, 2024

CLSD’s Market Whiplash: 35.04% YTD Rise, 62.89% Rise in 30 Days - The InvestChronicle

Oct 08, 2024
pulisher
Oct 07, 2024

Analyst Forecast For Clearside Biomedical Inc (NASDAQ: CLSD) - Stocks Register

Oct 07, 2024
pulisher
Oct 03, 2024

What is Clearside Biomedical Inc (CLSD) Stock Return on Shareholders’ Capital? - SETE News

Oct 03, 2024
pulisher
Oct 03, 2024

Financial Analysis: Clearside Biomedical Inc (CLSD)’s Ratios Unveil Key Insights - The Dwinnex

Oct 03, 2024
pulisher
Oct 03, 2024

Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of "Buy" by Brokerages - MarketBeat

Oct 03, 2024
pulisher
Oct 03, 2024

Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of “Buy” by Analysts - Defense World

Oct 03, 2024
pulisher
Oct 02, 2024

CLSD overperforms with a 5.51 increase in share price - US Post News

Oct 02, 2024

Clearside Biomedical Inc (CLSD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Clearside Biomedical Inc (CLSD) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Chong Ngai Hang Victor
Chief Medical Officer
Jun 24 '24
Buy
1.06
23,500
24,910
63,500
YERXA BENJAMIN R
Director
May 15 '24
Buy
1.31
7,813
10,235
17,957
Gibney Anthony S
Director
Apr 18 '24
Buy
1.30
93,290
121,277
100,000
Gibney Anthony S
Director
Apr 17 '24
Buy
1.25
6,710
8,388
6,710
Chong Ngai Hang Victor
CHIEF MEDICAL OFFICER
Mar 20 '24
Buy
1.60
30,000
48,000
30,000
WHITMORE BRADFORD T
10% Owner
Feb 07 '24
Buy
1.35
444,444
599,999
4,495,034
LASEZKAY GEORGE M
CEO
Jan 19 '24
Sale
1.27
18,000
22,860
466,577
Deignan Charles A.
Chief Financial Officer
Jan 19 '24
Sale
1.28
12,900
16,512
384,662
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
大文字化:     |  ボリューム (24 時間):